Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of the EP4 Antagonist CR6086 in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03163966
Recruitment Status : Recruiting
First Posted : May 23, 2017
Last Update Posted : December 22, 2017
Sponsor:
Information provided by (Responsible Party):
Rottapharm Biotech

Brief Summary:
CR6086 is a new, potent and selective, orally available, small molecule prostaglandin EP4 receptor antagonist, endowed with immunomodulatory properties. The pharmacological properties of CR6086, along with its oral bioavailability, predictable pharmacokinetics and good safety, make it the ideal candidate to be tested alone or in combination with methotrexate (MTX) in patients with early Rheumatoid Arthritis who are naïve to Disease-Modifying Antirheumatic Drugs (DMARDs). The compound has indeed the potential to provide a safer and more effective treatment than MTX (or other conventional synthetic DMARDs - csDMARDs), and could significantly improve the proportion of responder patients and avoid/delay the recourse to biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs).

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis, DMARD-naive and Early Disease Patients Drug: CR6086 Drug: Methotrexate Drug: Placebo Phase 2

Detailed Description:

There is growing evidence that EP4 receptors play an important role in the altered immune response observed in autoimmune diseases. These findings point to the EP4 receptor as a rational target for the development of novel Disease-Modifying Antirheumatic Drugs (DMARDs)/immunomodulators which, in addition, have direct anti-inflammatory properties. The potential for CR6086 to act as a DMARD was extensively demonstrated in a series of widely accepted models of arthritis in rodents, where oral CR6086 was effective in all the parameters examined, including oedema, clinical arthritis score, and histology. CR6086 performed much better than nonsteroidal anti-inflammatory drugs (NSAIDs, that lack the immunomodulatory properties of an EP4 receptor antagonist and are scarcely effective), better than first-line csDMARDs such as MTX, and similarly to immunosuppressive bDMARDs such as TNF-blockers, or tsDMARDs such as JAK inhibitors.

In the present study, CR6086 (or placebo) will be administered in a dose-response fashion for 12 weeks to DMARD-naïve patients with early Rheumatoid Arthritis, in combination with oral MTX. The treatment duration and study design will allow to test the effects of the new treatment on clinical outcomes of disease activity, laboratory biomarkers and imaging parameters.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double Blind, Placebo-controlled, Dose Response, Phase II, Multicentre Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of Oral CR6086 Administered at the Doses of 30, 90 or 180 mg Bid for 12 Weeks in Combination With Methotrexate, in DMARD-naïve Patients With Early Rheumatoid Arthritis
Actual Study Start Date : October 5, 2017
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CR6086 30 mg
CR6086 30 mg bid for 12 weeks as add-on to methotrexate (MTX) once weekly. MTX uptitrated to stable dosing as per standard guidelines
Drug: CR6086
oral CR6086 capsules

Drug: Methotrexate
oral Methotrexate tablets

Experimental: CR6086 90 mg
CR6086 90 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
Drug: CR6086
oral CR6086 capsules

Drug: Methotrexate
oral Methotrexate tablets

Experimental: CR6086 180 mg
CR6086 180 mg bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
Drug: CR6086
oral CR6086 capsules

Drug: Methotrexate
oral Methotrexate tablets

Experimental: Placebo
CR6086 matching placebo bid for 12 weeks as add-on to MTX once weekly. MTX uptitrated to stable dosing as per standard guidelines
Drug: Methotrexate
oral Methotrexate tablets

Drug: Placebo
oral CR6086 Placebo capsules




Primary Outcome Measures :
  1. American College of Rheumatology 20% improvement (ACR20) responder rate [ Time Frame: 12 weeks ]

Secondary Outcome Measures :
  1. ACR50 responder rate [ Time Frame: 12 weeks ]
  2. ACR70 responder rate [ Time Frame: 12 weeks ]
  3. Disease Activity Score on 28-joint count (DAS28) [ Time Frame: 12 weeks ]
  4. Clinical Disease Activity Index (CDAI) [ Time Frame: 12 weeks ]
  5. Simplified Disease Activity Index (SDAI) [ Time Frame: 12 weeks ]
  6. ACR/EULAR remission criteria [ Time Frame: 12 weeks ]
  7. Adverse Events [ Time Frame: 12 weeks ]
    number of patients with Adverse Events

  8. Routine Laboratory determinations [ Time Frame: 12 weeks ]
  9. Pharmacokinetics (PK) of Methotrexate and CR6086 in combination [ Time Frame: 12 weeks ]
    Main PK endpoint: AUCinf (ng.h/mL). Area under the plasma concentration vs time curve extrapolated to infinity

  10. Biochemical markers [ Time Frame: 12 weeks ]
    Serum biomarkers of disease activity

  11. Imaging biomarkers [ Time Frame: 12 weeks ]
    Dynamic Contrast-Enhanced MRI (DCE-MRI)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female aged ≥18 years.
  2. Patients with diagnosis of definite Rheumatoid Arthritis (RA) according to the 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) classification criteria.
  3. Disease duration no longer than 1 year (early RA).
  4. Patients must be naïve to any DMARDs (csDMARDs, or bDMARDs, or tsDMARDs) other than hydroxychloroquine.
  5. Patients with "moderate" disease activity as documented by a Disease Activity Score 28 (DAS28) (C-Reactive Protein - CRP) index score > 3.2.
  6. Patients with serum C-Reactive Protein (hsCRP) higher than the upper limit of normal.
  7. Patients positive for serum rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibodies (ACPA).

Exclusion Criteria:

  1. Rheumatic autoimmune disease other than RA, or current inflammatory joint disease other than RA, or non-inflammatory type of musculoskeletal condition (e.g., osteoarthritis or fibromyalgia) that in the Investigator's opinion is symptomatic and/or severe enough to interfere with the study procedures.
  2. History of gastric/duodenal ulcers and gastrointestinal bleeding, or gastrointestinal diseases known to interfere with the absorption or excretion of medications.
  3. Severe, progressive, or uncontrolled renal, hepatic, hematologic, gastrointestinal, metabolic, endocrine, pulmonary, cardiac or neurologic disease.
  4. Malignancy (with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ) active during the 12 months preceding the Screening Visit.
  5. Acute hepatitis (during the 3 months preceding the Screening Visit), chronic hepatitis, or HIV infection.
  6. History of alcohol or drug abuse, or
  7. allergy/sensitivity to lactose.
  8. Vaccination with live vaccines during the 6 weeks preceding the Screening Visit.
  9. Clinically significant abnormalities in haematology, serum alkaline-phosphatase, gamma-glutamyl-transferase, alanine aminotransferase, aspartate aminotransferase, total bilirubin, creatinine clearance, 12-lead ECG.
  10. Use of hydroxychloroquine during the 4 weeks preceding the Screening Visit.
  11. Treatment with oral corticosteroids, unless maintained at doses equivalent to ≤10 mg/day prednisone ≥7 days before the Screening Visit.
  12. Use of nonsteroidal anti-inflammatory drugs (NSAIDs).
  13. Use of other investigational drugs/treatments, or enrolment in a clinical trial during the 6 months preceding the Screening Visit.
  14. For women of childbearing potential:

    1. Pregnancy (i.e. positive pregnancy test at Screening) or breastfeeding
    2. Failure to agree to practice a highly effective method of contraception.
  15. For sexually active men with a female partner of childbearing potential: failure to agree to use contraception.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03163966


Contacts
Layout table for location contacts
Contact: Massimo D'Amato, MD +390399066069 massimo.damato@rottapharmbiotech.com
Contact: Nadia Brambilla, PhD +390399066055 nadia.brambilla@rottapharmbiotech.com

Locations
Layout table for location information
Czechia
Institute of Rheumatology Recruiting
Prague, Czechia
Sponsors and Collaborators
Rottapharm Biotech

Layout table for additonal information
Responsible Party: Rottapharm Biotech
ClinicalTrials.gov Identifier: NCT03163966     History of Changes
Other Study ID Numbers: CR6086-2-02
First Posted: May 23, 2017    Key Record Dates
Last Update Posted: December 22, 2017
Last Verified: December 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Methotrexate
Abortifacient Agents, Nonsteroidal
Abortifacient Agents
Reproductive Control Agents
Physiological Effects of Drugs
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Dermatologic Agents
Enzyme Inhibitors
Folic Acid Antagonists
Immunosuppressive Agents
Immunologic Factors
Antirheumatic Agents
Nucleic Acid Synthesis Inhibitors